Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2030-11-30

Summary

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.

• Phase: PHASE3

Details

• Lead Sponsor: Arcus Biosciences, Inc.
• Collaborator: Taiho Pharmaceutical Co., Ltd.
• Treatments: 130-nm albumin-bound paclitaxel; Gemcitabine; quemliclustat